Vimseltinib

Vimseltinib
Identifiers
	IUPAC name 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one;
CAS Number	1628606-05-2;
PubChem CID	86267612;
IUPHAR/BPS	11190;
DrugBank	DB17520;
ChemSpider	95499700;
UNII	PX9FTM69BF;
KEGG	D12238;
ChEMBL	ChEMBL5095202;
Chemical and physical data
Formula	C23H25N7O2
Molar mass	431.500 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C;
	InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27); Key:TVGAHWWPABTBCX-UHFFFAOYSA-N;

Vimseltinib is an investigational new drug that is being evaluated to treat tenosynovial giant cell tumor.^[1] It is a macrophage colony-stimulating factor receptor antagonist.^[2]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.